Portfolio Finder

Inovedis is developing a new surgical technique for rotator cuff ruptures based on a PEEK implant. This injury is by so far the most typical shoulder injury. The patented SINEFIX implant system allows refixation of the tendon with a simplified surgical technique and is optimized for minimally invasive surgery. The technique is easy and quick to learn for the surgeon, minimizing complications due to surgical mistakes. The novel surgical principle suggests significant time and cost reductions as well as improved outcomes. Inovedis was founded in 2016. The company started operations in 2019.

Intelligent fluids GmbH is designing innovative high performance cleaning fluids for industrial application that are unique in the world. These intelligent fluids® are based on a groundbreaking, patented technology that combines gentle ingredients to create highly dynamic phase fluids tailored to specific needs. The highly effective fluids achieve their outstanding performance due to physical effects, no chemical dissolving or etching takes place. The fluids therefore combine high performance and sustainability.

KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare.

Exit since Feb. 2011. Purchaser: Evotec AG

The founders of Kumovis GmbH have set themselves the goal of enabling the additive production of plastic implants and are developing innovative 3D printers specifically for medical products. Kumovis focuses on the processing of high-performance polymers, which are already established in medical technology. With the Kumovis system these plastics can be processed individually, decentrally and with a high degree of design freedom. Through the integration of a unique air circuit including filter units, the technology enables a clean room environment within the build chamber. The contamination of the component with foreign particles can be avoided. As a result, the Kumovis printer can produce products such as implants cost-effectively and at the same time patient-individualized.

LignoPure GmbH is a spin-off of the TU Hamburg that enables the valorization of Lignin, a byproduct of ethanol biorefineries and the pulp and paper industry, via a proprietary technology. The startup is pioneering in the use of lignin in care products and biobased high-performance materials. As key technology partner, LignoPure supports their customers in launching their own innovative and sustainable products by not only providing the tailored raw material but offering development services in the areas of material and life sciences.

Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood collected during the operation. The product consists of a combination of an antibody and filter and serves to remove cancer cells from the blood.

lino Biotech AG was incorporated as a ETH Zurich spin-out in Zürich, Switzerland, in March 2020, and is venture backed by Roche Venture Fund, High-Tech Gründerfonds and several lifescience family offices. lino offers industry partners and researchers a unique way to study molecular interactions in living cells and crude biosystems.

Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.



LOEWI GmbH is a scientific spin-off of the TU München with the mission to make personalized health and nutrition available to everyone by combining science and technology. LOEWI's patented personalization concept analyzes health relevant data of customers and patients, makes the analysis available via LOEWI's Health Profile (Medical Software Class I), and creates personalized nutrient recommendations and therapies using a sophisticated recommendation algorithm, which are 100% tailored to the personal needs of each customer and patient.

Lymphatica Medtech develops medical devices for lymphatic disease treatment. The first product, LymphoDRAIN, is the worldwide first active lymphatic bypass for the treatment of chronic lymphedema, a disabling disease affecting millions of people worldwide.
Lymphatica developed its implantable drainage technology as a results of years of research at the Lausanne Federal Institute of Technology (EPFL) and of the Lausanne University Hospital (CHUV).

m2p-labs supplies microbioreactor systems focusing on micro fermentations and automated solutions for screening and bioprocess development. The product portfolio comprises high-throughput BioLector® micro fermentation systems, microtiter FlowerPlate® plates, and automated cultivation RoboLector® platforms, an integration of the BioLector® tool into a liquid handling system.
Proprietary online monitoring technology increases the number and the information content of microbial experiments, either aerobic, microaerophilic, or strictly anaerobic. Experiments can be conducted with excellent efficiency and high quality at low costs in microscale.

Mbiomics is a Munich based microbiome startup company which was founded by Dr. Laura Figulla (CEO), Dr. Johannes Wöhrstein (CTO), and Dr. Markus Rinecker (CMO) in 2020. With its proprietary microbiome profiling technology at hand, mbiomics is uniquely positioned to understand microbiome modulation and to design effective microbiome therapies.

MDTB stands for drugs, which are based on the immunomodulating drug substance Desacell®.
Desacell® is an advanced drug platform based on MSC (Mesenchymal Stromal Cells) and addresses many inflammatory-associated diseases for which there are currently no satisfactory therapies and which lead to high mortality or poor quality of life. Examples include septic shock, acute GvHD and the lung disease BPD.
The mission of MDTB Cell Manufacturing GmbH is the industrial-pharmaceutical production of MSC-based drugs in Germany as clinically well manageable Advanced Therapy Medical Products (off-the-shelf/ready-to-use) to significantly improve the health of affected patients. The manufacturing costs and the progress made in scaling up should also enable application in large patient groups.
Desacell® is currently being tested internationally in several clinical studies.

mediaire GmbH was founded in 2018 in Berlin by experienced MRT and AI experts in order to support radiologists with innovative software solutions for the automatic diagnosis of MRT images. mediaire's solutions can be fully integrated into the internal IT infrastructure of radiology centers to ensure a smooth workflow and the highest possible protection of sensitive patient data. The first product md.Brain, which can be used for early detection and follow-up of neurodegenerative diseases, is already certified as a medical device and is therefore available for immediate use. Among the co-founders are two medical physicists with expertise in MRI and CI (Dr. Andreas Lemke and Dr. Jörg Döpfert), as well as two experienced scientists and specialists in radiology (Prof. Dr. med. Henrik Michaely and Prof. Dr. med. Michael Fenchel).

miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic methods. The first product, based on the quantification of microRNA, is a blood test for the detection of testicular cancer. The high sensitivity and accuracy of the test improves the diagnosis and therapy of patients significantly and reduces the costs for the health care system. miRdetect has developed a patented platform technology, which allows the exact and reliable quantification of small amounts of genetic material in body fluids. This robust method represents the basis for the development of additional diagnostic tests.

Mosanna is a Swiss Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. We carefully select innovative medicines for further development using the best contract research organisations in the specific specialised field. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.

multiBIND develops innovative solutions for molecular biology, healthcare and agriculture. bioDECONT® and bioCLEAN represent biocompatible disinfection and decontamination in laboratories, hospitals and agriculture.



MYR develops a novel, peptide-based, first-in-class drug (entry inhibitor) for the treatment of chronic hepatitis B and Delta infections. Clinical phase IIb currently in preparation.

Nebula Biocides GmbH was founded in 2019 as a spin-off from the Leibniz Institute for Plasma Science and Technology (INP) by the scientists Dr. Jörn Winter, Dr. Ansgar Schmidt-Bleker and the director of INP Prof. Dr. Klaus-Dieter Weltmann. With the aim of providing comprehensive protection against infectious pathogens, the company develops application-oriented disinfection solutions that reliably kill not only bacteria and viruses but also persistent bacterial spores.

neotiv is a spin-off of the Otto von Guericke University in the German city of Magdeburg in close collaboration with the Magdeburg site of the German Centre for Neurodegenerative Diseases (DZNE). neotiv incorporates the latest scientific findings from the fields of neuroscience and dementia research into mobile software that can be used on smartphones and tablets. Our work focuses on the development of a digital assistant that can monitor and aid users' memories and provide support for patients with dementia. neotiv is also designed to improve the early detection of Alzheimer's dementia and to facilitate efficacy monitoring for new therapies as they become available in the future. Biologically and anatomically valid and user-oriented measurements of specific memory functions, which can be carried out on a regular basis, form the core of the development of neotiv. The measurements focus on regions of the brain that are affected in the early stages of Alzheimer's disease. The vision behind neotiv is to (i) help reducing risk factors for cognitive decline by making lifestyle change simple and cognitive health measurable and (ii) to enable the innovative early detection of cognitive difficulties and dementia risk.

Nia Health is a spin-off of the Charité Universitätsmedizin Berlin. The start-up develops a clinical diagnosis and therapy system for the continuous digital support of patients with chronic skin conditions. With its platform, Nia Health addresses an often highly underserved patient population and generates treatment-relevant real world evidence. With its innovative machine vision approach, Nia Health enables accurate documentation of disease and therapy progression and thus optimised treatment. The company works closely with German patient associations and leading clinicians and has already won reputable customers from
the insurance and pharmaceutical industries. Amongst others, the Berlin-based company has developed the award-winning apps in the fields of atopic dermatitis (Nia) and psoriasis (Sorea), which were the first digital medical products of their kind to be approved worldwide. The digital medical solutions from Nia Health provide daily support for thousands of patients and their families.

In order to successfully treat the infected patient, you have to recognize and diagnose most reliably the infecting microbe.
Noscendo changes the way infection causative microbes are identified. Through a paradigm shift we introduce by using proprietary algorithms and software harnessing next generation sequencing, we identify pathogens from cell free nucleic acids in patient samples and thereby aid intensive care clinicians in their daily task to find the right decisions, enabling a targeted and successful treatment in an actionable timeframe.

NovaPump GmbH is developing and realising a leading solution for a novel right ventricular assist device (RVAD) with clear USPs (the only percutaneous device with pulsatile support).
NovaPump’s catheter-based heart pump PERKAT™ can be implanted within minutes in acute situations involving acute right heart failure, cardiogenic shock or acute right heart insufficiency and offers highly efficient pulsatile heart support in combination with the existing IABP (Intra-Aortic Balloon Pump) technology as a drive.
A perspective application of PERKAT™ as a bi-ventricular assist device (bi-VAD) is also planned for the near future.

Numaferm developed a platform technology for fast, scalable and cost-efficient production of peptides and proteins, with a focus on pepteins (PEPTides & protEINS) in the range of 30-500 amino acids. They serve customers from pharma, biotech, agriculture, and cosmetics offering peptides and proteins at highest qualities, within weeks, in a sustainable way. In this context partnership deals with global CDMO PolyPeptide and the world’s leading animal health company Zoetis were closed.
Founded in 2017 as a spin-out of Düsseldorf University, Numaferm has grown to over 20 staff.

O11 biomedical, a visionary medical technology start-up that emerged as part of BioTex at RWTH Aachen University/ University Hospital Aachen 2022, aims to improve survival rates and quality of life for patients struggling with severe respiratory distress. O11 has developed a disruptive therapy that allows patients to "breathe out" carbon dioxide via the intestines, freeing them from hours of agonizing ventilation therapy: RESPILIQ™. With currently 6 employees and its own production and development facility in Aachen, O11 is ideally positioned for the future.

OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.

oncgnostics develops - based on proprietary epigenetic biomarkers - highly reliable molecular in-vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in oncology.

Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium. Pantherna is based in Hennigsdorf (Brandenburg) close to Berlin, Germany.

PEPperPRINT produces customized ultra-high density peptide microarrays and uses individualized peptide libraries for drug development, antibody characterization, and protein biomarker discovery.